| 06.01. | Albireo Increases 2021 Bylvay (odevixibat) Sales Guidance |  |
| 05.01. | ALBIREO PHARMA : Increases 2021 BylvayTM (odevixibat) Sales Guidance - Form 8-K/A | |
| 05.01. | ALBIREO PHARMA, INC. Results of Operations and Financial Condition, Change in Director.. | |
| 05.01. | Albireo Increases 2021 Bylvay™ (odevixibat) Sales Guidance | |
| 05.01. | ALBIREO PHARMA, INC. : Results of Operations and Financial Condition, Change in Directors .. | |
| 05.01. | ALBIREO PHARMA : Increases 2021 BylvayTM (odevixibat) Sales Guidance - Form 8-K | |
| 05.01. | Albireo Pharma, Inc. Announces Resignation of Roger A. Jeffs as Independent Director | |
| 03.01. | Immix Biopharma Shares More Than Double on FDA Designation | |
| 2021 | Albireo Pharma's Early Stage Trial Confirms Safety, Tolerability of Liver Disease Drug | |
| 2021 | Albireo Announces Positive Topline Data from Phase 1 Study of A3907 | |
| 2021 | Albireo Announces Positive Topline Data from Phase 1 Study of A3907 | |
| 2021 | Albireo Presenting New Bylvay™ (odevixibat) Data at NASPGHAN 2021 | |
| 2021 | Albireo Pharma, Inc. Presenting New Bylvay™ Data at NASPGHAN 2021 | |
| 2021 | ALBIREO PHARMA : Announces Changes to R&D Organization - Form 8-K | |
| 2021 | ALBIREO PHARMA, INC. : Entry into a Material Definitive Agreement, Change in Directors or .. | |
| 2021 | Albireo Announces Changes to R&D Organization | |
| 2021 | Albireo Pharma, Inc. Announces Executive Changes | |
| 2021 | Albireo Expands Leadership with Constantine Chinoporos as Chief Business Officer | |
| 2021 | Albireo Pharma, Inc. Announces Constantine Chinoporos as Chief Business Officer | |
| 2021 | ALBIREO PHARMA : Post-AASLD Business Update | |
| 2021 | Albireo Announces New Phase 3 Data for Bylvay™ (odevixibat) in PFIC and First Rev.. | |
| 2021 | Albireo Announces New Phase 3 Data for Bylvay? in Pfic and First Reveal of New Next Gen.. | |
| 2021 | Albireo to Present at Upcoming Investor Conferences | |
| 2021 | Albireo Pharma Swings to Q3 Gain on Sale of Priority Review Voucher; Shares Fall | |
| 2021 | ALBIREO PHARMA, INC. Management's Discussion and Analysis of Financial Condition and R.. | |
| 2021 | Albireo Pharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months End.. | |
| 2021 | Albireo Reports Q3 Financial Results and Business Update - Form 8-K | |
| 2021 | Earnings Flash (ALBO) ALBIREO PHARMA Posts Q3 Revenue $3.7M | |
| 2021 | Albireo Reports Q3 Financial Results and Business Update | |
| 2021 | Albireo to Report Third Quarter 2021 Financial Results on November 4 | |
| 2021 | ALBIREO PHARMA : to Showcase New Data at AASLD The Liver Meeting 2021 | |
| 2021 | Albireo to Showcase New Data at AASLD The Liver Meeting® 2021 | |
| 2021 | ALBIREO PHARMA : Announces Exclusive Licensing Agreement with Jadeite Medicines for Bylvay.. | |
| 2021 | ALBIREO PHARMA : Signs Bylvay Licensing Deal With Jadeite Medicines | |
| 2021 | ALBIREO PHARMA : Announces Exclusive Licensing Agreement with Jadeite Medicines for Bylvay.. | |
| 2021 | Albireo Pharma, Inc. Announces Exclusive Licensing Agreement with Jadeite Medicines for.. | |
| 2021 | Albireo Recognizes PFIC Awareness Day 2021 | |
| 2021 | ALBIREO PHARMA : Recognizes PFIC Awareness Day 2021 | |
| 2021 | MIRUM PHARMACEUTICALS : oral drug becomes first U.S. approved Alagille syndrome therapy | |
| 2021 | ALBIREO PHARMA : Announces Bylvay (odevixibat) Now Available in Germany | |
| 2021 | ALBIREO PHARMA : Launches Bylvay in Germany | |
| 2021 | ALBIREO PHARMA : Announces Bylvay® (odevixibat) Now Available in Germany | |
| 2021 | Albireo Pharma, Inc. Announces Bylvay® Now Available in Germany | |
| 2021 | ALBIREO PHARMA : Reports Inducement Grant Under Nasdaq Listing Rule 5635(4) | |
| 2021 | ALBIREO PHARMA : Receives UK MHRA Approval of Bylvay (odevixibat) | |
| 2021 | Albireo Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | |
| 2021 | ALBIREO PHARMA : Wins UK Ok of Bylvay for Progressive Familial Intrahepatic Cholestasis | |
| 2021 | ALBIREO PHARMA : Receives UK MHRA Approval of Bylvay® (odevixibat) | |
| 2021 | Albireo Pharma, Inc. Receives UK MHRA Approval of Bylvay® | |
| 2021 | ALBIREO PHARMA : To Sell Priority Review Voucher For $105 Million | |
| 2021 | ALBIREO PHARMA : PRV was granted to Albireo with the FDA approval of BylvayTM (odevixibat).. | |
| 2021 | ALBIREO PHARMA, INC. : Entry into a Material Definitive Agreement, Financial Statements an.. | |
| 2021 | Albireo Sells Priority Review Voucher (PRV) for $105 Million | |
| 2021 | Albireo to Present at Upcoming Investor Conferences | |
| 2021 | ALBIREO PHARMA : Enters Deal With Genpharm to Commercialize Liver Disease Drug in Saudi Ar.. | |
| 2021 | ALBIREO PHARMA : Management's Discussion and Analysis of Financial Condition and Results o.. | |
| 2021 | ALBIREO PHARMA : Earnings Flash (ALBO) ALBIREO PHARMA Reports Q2 Revenue $2.4M, vs. Street.. | |
| 2021 | ALBIREO PHARMA : Reports Q2 Financial Results and Business Update | |
| 2021 | Albireo Pharma, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 202.. | |
| 2021 | Albireo to Present at the 2021 Wedbush PacGrow Virtual Healthcare Conference | |
| 2021 | Albireo to Report Second Quarter 2021 Financial Results on August 5 | |
| 2021 | ALBIREO PHARMA : Announces FDA Approval of Bylvay (odevixibat), the First Drug Treatment f.. | |
| 2021 | ALBIREO PHARMA : Receives European Marketing Authorization of Bylvay™ (odevixibat), .. | |
| 2021 | ALBIREO PHARMA, INC. : Other Events, Financial Statements and Exhibits (form 8-K) | |
| 2021 | MULTIMEDIA UPDATE - Albireo Announces FDA Approval of Bylvay™ (odevixibat), the F.. | |
| 2021 | ALBIREO PHARMA : Bylvay Receives FDA Approval as Progressive Familial Intrahepatic Cholest.. | |
| 2021 | Albireo Announces FDA Approval of Bylvay™ (odevixibat), the First Drug Treatment .. | |
| 2021 | Albireo Pharma, Inc. Announces FDA Approval of Bylvay™, the First Drug Treatment for Pa.. | |
| 2021 | ALBIREO PHARMA : Receives European Marketing Authorization of Bylvay (odevixibat), the Fir.. | |
| 2021 | ALBIREO PHARMA : Obtains European Marketing Approval for Rare Liver Disease Treatment | |
| 2021 | ALBIREO PHARMA : Receives European Marketing Authorization of Bylvay™ (odevixibat), .. | |
| 2021 | Albireo Pharma, Inc. Announces European Commission Authorization of Bylvay, the First D.. | |
| 2021 | Albireo to Present at the William Blair Biotech Focus Conference 2021 | |
| 2021 | ALBIREO PHARMA : to Present at Piper Sandler's Virtual EASL Takeaway Day | |
| 2021 | ALBIREO PHARMA : to Present at Piper Sandler's Virtual EASL Takeaway Day | |
English (USA)
English (UK)
English (Canada)
Deutsch (Deutschland)
Español
Français (France)
Italiano
Nederlands (Nederland)
Nederlands (België)
Bericht
